16.07.2010 • NewsU.S. FDAMcNeil Consumer HealthcareTyenol

J&J Revamping Tylenol Plant, Slashing Jobs There

Johnson & Johnson on Thursday said it aims to revamp a now-closed Pennsylvania plant that made Tylenol and other consumer medicines that have been recalled in recent months due to quality-control lapses and eliminate 300 of the factory's more than 400 employees.

J&J said other company plants will help produce medicines once made at the factory as it is retrofitted, and reaffirmed that most of the products are unlikely to become available before the end of 2010.

The company, in a statement, also said it earlier on Thursday had given the U.S. Food and Drug Administration an expected "comprehensive action plan" that listed other proposed means of correcting quality shortcomings at its factories. They have led to four major recalls of J&J consumer medicines in the past year that have tarnished the reputation of the company and its iconic brands.

The company said its McNeil Consumer Healthcare unit had already begun taking a number of significant steps to enhance quality controls, and will use outside experts to go further. One of the biggest recalls came on April 30, when J&J took 40 widely used children's medications off the market, including painkillers Tylenol and Motrin and allergy treatments Benadryl and Zyrtec.

The plant in Fort Washington, Pa. was closed after FDA inspectors said they found thick dust, grime and contaminated ingredients in the facility.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
12.12.2024 • NewsPharma

Austria: A Hotspot for Life Sciences

An Attractive and Highly Sought-after Business Location

The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.